PRINCETON, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Cytogen Corporation today announced that it will report its third-quarter 2006 financial results on Thursday, November 2, 2006 at approximately 4:00 p.m. EST. The announcement will be followed by a live conference call that will begin at approximately 4:15 p.m. EST. Michael D. Becker, president and chief executive officer will host the call and discuss the Company's financial results and business activities for the period.
All interested parties may access the call by using the following information:
Domestic Dial-In: 866-362-5158
International Dial-In: 617-597-5397
Access Code: 54929515
A live audio of the conference call will be simultaneously broadcast over the internet and can be accessed by going to the "Investor Relations" section of the Company's website at http://www.cytogen.com.
For those unable to listen to the live audio, the event will be available for replay beginning approximately one hour after the call and continuing for seven days thereafter. The replay can be accessed using the following information:
Domestic Dial-In: 888-286-8010
International Dial-In: 617-801-6888
Access Code: 59958421
About Cytogen
Founded in 1980, Cytogen is a biopharmaceutical company dedicated to advancing the care of cancer patients by acquiring, developing, and commercializing innovative pharmaceutical products. The Company's specialty sales force currently markets QUADRAMET(R), PROSTASCINT(R), and SOLTAMOX(R) to the U.S. oncology market. QUADRAMET is approved for the treatment of pain in patients whose cancer has spread to the bone, PROSTASCINTis a PSMA-targeting monoclonal antibody-based agent to image the extent and spread of prostate cancer, and SOLTAMOX is the first liquid hormonal therapy approved in the U.S. for the treatment of breast cancer in adjuvant and metastatic settings. In early 2007, Cytogen plans to introduce its fourth marketed product to the U.S. market, CAPHOSOL(R), a prescription medical device for the treatment of oral mucositis and dry mouth. The Company is also developing CYT-500, a third-generation radiolabeled antibody to treat prostate cancer. Cytogen's product-focused strategy focuses on attaining sustainable growth through clinical, commercial, and strategic initiatives.
Cytogen CorporationCONTACT: Susan Mesco of Cytogen Corporation, +1-609-750-8213
Web site: http://www.cytogen.com/
